+

WO2003041637A2 - Compositions lyophilisees d'anticorps monoclonaux - Google Patents

Compositions lyophilisees d'anticorps monoclonaux Download PDF

Info

Publication number
WO2003041637A2
WO2003041637A2 PCT/US2002/033272 US0233272W WO03041637A2 WO 2003041637 A2 WO2003041637 A2 WO 2003041637A2 US 0233272 W US0233272 W US 0233272W WO 03041637 A2 WO03041637 A2 WO 03041637A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
monoclonal antibody
lyophilized
disaccharide
hes
Prior art date
Application number
PCT/US2002/033272
Other languages
English (en)
Other versions
WO2003041637A3 (fr
Inventor
Tracy Chen
Glen Tolman
Original Assignee
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc. filed Critical Centocor, Inc.
Priority to CA002466641A priority Critical patent/CA2466641A1/fr
Priority to MXPA04004459A priority patent/MXPA04004459A/es
Priority to EP02773798A priority patent/EP1455822A4/fr
Priority to JP2003543524A priority patent/JP2005508992A/ja
Publication of WO2003041637A2 publication Critical patent/WO2003041637A2/fr
Publication of WO2003041637A3 publication Critical patent/WO2003041637A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Definitions

  • the present invention relates to the field of pharmaceutical compositions and the manufacture of lyophilized monoclonal antibody and antibody fragment compositions. More particularly, the invention relates to a lyophilized composition of abciximab and infliximab.
  • Abciximab is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3 which inhibits platelet aggregation in humans.
  • Infliximab is the chimeric human-murine monoclonal antibody against tumor necrosis factor.
  • the composition exhibits high glass transition temperatures and improved stability BACKGROUND OF THE INVENTION
  • An essential feature in the development of a protein therapeutic is to design a formulation that is stable during shipment and storage before administration to a patient.
  • an aqueous formulation is the easiest and most economical to handle for the manufacturer and easiest to administer to the patient.
  • most preparations are prepared and stored in a liquid state.
  • precise control of storage conditions such as refrigeration and minimization of agitation is necessary to retain stability. Such conditions are often seen as a drawback to commercial application of the product.
  • the process has numerous advantages in that the aqueous solution can be processed and filled into dosage containers in a liquid state, dried at low temperatures thereby eliminating adverse thermal effects, and stored in the dried state where it may be more stable.
  • the lyophilized product is ordinarily rapidly soluble and is easily reconstituted prior to administration to a patient.
  • appropriate care must be taken to choose the conditions and excipients for use in the lyophilization process.
  • most protein preparations are at least partially denatured by the freezing and dehydration stresses encountered during lyophilization. Additionally, excipients should be chosen that assure stability during long term storage in the dried solid.
  • the glass transition temperature (Tg') of the amorphous phase in the product, which contains the protein must exceed the planned storage temperature. Since water is a plasticizer of the amorphous phase, low residual moisture is needed to insure that Tg' is greater than the highest temperature encountered during shipping and storage.
  • the Tg' of the liquid state prior to lyophilization is a critical factor in lyophilization, and is determined by excipients in the liquid state and container configuration. In the case where a dual chamber syringe such as a Lyo-Ject syringe is to be used, a composition with a high Tg' is necessary to be compatible with the uniqueness of the syringe design.
  • a monoclonal antibody is a protein molecule produced by fusing a chosen B cell line with an immortal myeloma cell line to produce hybridomas, immortal cells that secrete only the selected antibody type of the selected B cell clone.
  • each antibody is formed by the interaction of two identical "heavy" chains and two identical light chains, all of which combine to form a Y shape (the heavy chains span the entire Y, and the light chains the two arms only.
  • An antibody according to the present invention includes any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to at least one complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework region, or any portion thereof, that can be incorporated into an antibody of the present invention.
  • An antibody of the invention can include or be derived from any mammal, such as but not limited to a human, a mouse, a rabbit, a rat, a rodent, a primate, or any combination thereof, and the like.
  • An antibody fragment as used in the present invention includes the fragment of the immunoglobulin molecule known as the Fab containing the CDR antigen binding site, generated by cleavage of the antibody with the protease papain which cuts at the "hinge" region of the Y shaped antibody molecule producing two Fab fragments.
  • monoclonal antibodies are protein molecules, they are generally formulated as aqueous solutions for injection. As such, they have limited shelf life and must be stored under controlled conditions as discussed above.
  • the monoclonal antibody abciximab (REOPRO®), is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3.
  • Abciximab binds to the glycoprotein (GP) llb/llla receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin ( ⁇ v ⁇ s) receptor found on platelets and vessel wall endothelial and smooth muscle cells. It is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. Abciximab is sold commercially as a clear, colorless, sterile solution for intravenous use and must be stored under refrigerated conditions at 2 to 8 S C. A detailed description of abciximab is disclosed in US patent 5,770,198 hereby incorporated by reference into the present application.
  • the monoclonal antibody infliximab (REMICADE®) is a chimeric lgG1 k monoclonal antibody with an approximate molecular weight of 149,100 daltons. It is composed of human constant and murine variable regions. Infliximab binds specifically to human tumor necrosis factor alpha (TNF(alpha)) with an association constant of 10 10 M "1 . Infliximab is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses. REMICADE is currently supplied as a sterile, white, lyophilized powder for intravenous infusion.
  • each single-use vial contains 100 mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium phosphate, monohydrate, and 6J mg dibasic sodium phosphate, dihydrate. No preservatives are present.
  • infliximab is disclosed in US patent 5,656,272 hereby incorporated by reference into the present application.
  • a lyophilized product Prior to administration to a patient, a lyophilized product has to be reconstituted with sterile water.
  • a convenient way to do this is to deliver the product in a dual chamber syringe such as a Lyo-Ject® syringe
  • the Lyo-Ject is a dual-chamber prefilled syringe with in situ lyophilized drug.
  • the lyophilized drug and diluent are contained in dual chambers in the same syringe and can be easily reconstituted prior to injection.
  • Tg' glass transition temperature
  • the object of the present invention is to provide a monoclonal antibody composition with enhanced stability by the application of lyophilization to the aqueous solution. Another object is to provide a lyophilized monoclonal antibody product which exhibits the high Tg' to be compatible with a dual chamber syringe.
  • the invention concerns an improved solid pharmaceutical composition comprising a lyophilized monoclonal antibody composition that exhibits enhanced stability in the dry form and a high glass transition temperature.
  • a lyophilized monoclonal antibody composition comprising a therapeutically active monoclonal antibody or fragment thereof in admixture with a stabilizing excipient comprised of a combination of a disaccharide and a hydroxyethyl starch
  • the monoclonal antibody is abciximab.
  • a facile process for the production of the solid composition is also provided by the present invention, comprising the steps of:
  • the therapeutically active component of this invention is a monoclonal antibody as described above.
  • the monoclonal antibody is abciximab as disclosed in U.S. Pat. Nos. 5,770,198 and 5,976,532, hereby incorporated by reference into the present application.
  • the monoclonal antibody protein for use in the invention may be prepared by any techniques that are well known to those skilled in the art, for example by purification from a cell line, a mixed cell line, an immortalized cell or clonal population of immortalized cells, as well known in the art.
  • Monoclonal antibodies useful in the present invention include abciximab, discussed above and the anti- TNF ⁇ chimeric monoclonal antibody (infliximab, REMICADE®) Methods for the production of the abciximab monoclonal antibody polypeptides are described in U.S. Pat. No. 5,770,198, hereby incorporated by reference into the present application. Methods for the production of the infliximab monoclonal antibody are described in U.S. Pat. No. 5,656,272 hereby incorporated by reference into the present application.
  • the lyophilized monoclonal antibody composition is manufactured from the aqueous solution containing approximately 5 mg/ml polypeptide.
  • Appropriately sized vials are filled with the aqueous solution with a fill volume of 2 to 5 ml per vial.
  • the vials are then frozen in the lyophilization chamber, preferably at a gradual rate of 0.5°-1 ° C./min, for approximately 2 hours to a temperature of ⁇ -40° C. or until completely frozen.
  • the lyophilization chamber pressure is reduced to about 100 microns Hg or less.
  • the shelf temperature is then raised to -20° C- +20° C. and held until sublimation of ice is substantially complete.
  • the shelf temperature is then gradually raised, preferably at a rate of 0.5° C./min to 30° C and held for about 2 hours or more.
  • the lyophilized dry composition prepared by the method of the instant invention exhibits enhanced stability and can be stored at room temperature for 6 months or greater depending on product specifications.
  • the sealed vials are intended for use as single dose formulations following reconstitution with appropriate volumes of Sterile Water for Injection. It is intended that the filled vials will allow rapid dispersion of the solid composition upon reconstitution with water in situ giving an appropriate sterile solution of the desired monoclonal antibody concentration for administration.
  • the lyophilized product is generally a white powder which undergoes reconstitution in about 1-5 minutes by swirling the vial.
  • the vials utilized should be capable of maintaining a sterile environment by being hermetically sealed by means of a stopper and overseal.
  • the vials should be of an appropriate size, considering the volume of solution to be held upon reconstitution of the lyophilized composition; and should be made of appropriate material, generally Type I glass.
  • the stopper means employed, preferably sterile rubber closures or an equivalent, should provide the appropriate seal but allow entry for the purpose of introducing the diluent for reconstitution.
  • the lyophilized monoclonal antibody composition of the invention exhibits enhanced stability in the dry form and a high glass transition temperature and is obtained by lyophilizing the monoclonal antibody in the presence of a stabilizing excipient comprised of a combination of a disaccharide and a hydroxyethyl starch.
  • a stabilizing excipient comprised of a combination of a disaccharide and a hydroxyethyl starch.
  • the hydroxyethyl starch (HES) used in the invention is obtained from native starch after partial hydrolysis and substitution of the hydroxy groups by hydroxyethyl groups (see E. Nitsch, Chemie der Hydroxyethystarke (HES), Beitr. Anaesth. Intesivmed., 26 (1988) 15-26..
  • HES is a known stabilizing agent in the freeze drying of biological material and comes in various commercially available forms depending on the degree of molar substitution.
  • the HES has an average molecular weight of 10,000 - 200,000, preferably 20,000-60,000.
  • the disaccharide is selected from known disaccharides, such as sucrose, trehalose, maltose and lactose, with the non-reducing disaccharides such as sucrose being preferrred.
  • a combination of HES and disaccharide is employed in the lyophilizing process.
  • the desired Tg' and stabilizing effect can be customized for the monoclonal antibody preparation employed.
  • the combination of HES and disaccharide is employed at an appropriate ratio to provide a Tg' of greater than -26 9 C and sufficient stabilizing effect.
  • the ratio of sucrose to HES is 6:4 but a range of 10:1 to 4:6 can be employed.
  • the disaccharide and HES should preferably be contained in the aqueous monoclonal antibody solution in an amount of not less than 1 mg, more preferably 3 mg to 65 mg, per milliliter of said solution.
  • the combination of disaccharide and HES provides sufficient stability, minimizes aggregation, shortens the lyophilization cycle time and minimizes the formation of visible particles.
  • Monoclonal antibody preparation formulated in accordance with the invention exhibits long term stability on storage of 6 months or greater at room temperature.
  • the lyophilized monoclonal antibody product of the present invention is generally prepared as follows: to an aqueous solution containing monoclonal antibody in an appropriate concentration, there is added the disaccharide HES in an amount sufficient to make a concentration of not less than 1 mg/ml, preferably 5 to 65 mg/ml. The above mentioned optional excipients may also be added . The therapeutic antibody product is then lyophilized in accordance with the above mentioned procedure.
  • ingredients may be included in the formulation of the product of the present invention. These may include buffers to affect the pH of the solution, wetting or emulsifying agents, antimicrobial agents, preservatives, surfactants, isotonizing agents and the like. Also, bulking agents such as sodium bicarbonate, lactose, maltose, mannitol, sorbitol, or dextrose may be included to improve the characteristics of the freeze-dried cake.
  • buffers to affect the pH of the solution
  • wetting or emulsifying agents such as sodium bicarbonate, lactose, maltose, mannitol, sorbitol, or dextrose
  • lactose maltose
  • mannitol mannitol
  • sorbitol or dextrose
  • the lyophilized monoclonal antibody composition of the present invention is preferably formulated for intravenous administration when reconstituted as a solution.
  • EXAMPLE 1 Abciximab monoclonal antibody composition containing approximately 2 mg/ml total antibody is prepared in accordance with the procedures outlined in Coller et al., U.S. Pat. No. in US patent 5,770,198.
  • sucrose HES in an amount sufficient to make a concentration of not less than 2 mg/ml, preferably 5 to 65 mg/ml and the resultant solution is then sterile filtered.
  • the above mentioned optional excipients may also be added .
  • the therapeutic antibody product is then lyophilized in accordance with the following procedure: 5 ml vials containing 2 ml drug product are filled and placed into the lyophilization chamber. Shelf temperature is lowered at 0.5 e -1 9 C/min. to -40° C. and held below -40 s C. for 2 hours.
  • Chamber pressure is then reduced to 100 microns Hg, the shelf is ramped to 0° C. at 0.5° C./min. and held for 48 hours. Shelf temperature is then raised to approximately +30 Q C. at 0.5 9 C./min. and held for 12 hours. The chamber is then brought to atmospheric pressure with dry nitrogen and the vials are stoppered and removed from the chamber and sealed.
  • the vial contents Prior to use in therapy, the vial contents are reconstituted with 5 ml of Sterile Water for Injection, physiological saline or injectable glucose solution to yield the original concentration of solids in the vial.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition pharmaceutique solide améliorée comprenant une composition lyophilisée d'anticorps monoclonaux qui manifeste une meilleure stabilité sous forme séchée et a une température de transition vitreuse élevée. Selon l'invention, une composition lyophilisée d'anticorps monoclonaux comprend un anticorps monoclonal thérapeutiquement actif ou un fragment de celui-ci, mélangé à un excipient stabilisateur comprenant une combinaison de disaccharide et d'amidon hydroxyéthylique. De préférence, l'anticorps monoclonal est l'abciximab.
PCT/US2002/033272 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux WO2003041637A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002466641A CA2466641A1 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux
MXPA04004459A MXPA04004459A (es) 2001-11-09 2002-10-18 Composiciones liofilizadas de anticuerpo monoclonal.
EP02773798A EP1455822A4 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux
JP2003543524A JP2005508992A (ja) 2001-11-09 2002-10-18 凍結乾燥されたモノクローナル抗体組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34206301P 2001-11-09 2001-11-09
US60/342,063 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003041637A2 true WO2003041637A2 (fr) 2003-05-22
WO2003041637A3 WO2003041637A3 (fr) 2004-01-22

Family

ID=23340162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033272 WO2003041637A2 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux

Country Status (7)

Country Link
EP (1) EP1455822A4 (fr)
JP (1) JP2005508992A (fr)
AR (1) AR037304A1 (fr)
CA (1) CA2466641A1 (fr)
MX (1) MXPA04004459A (fr)
TW (1) TW200303213A (fr)
WO (1) WO2003041637A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
WO2010066634A1 (fr) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Procédé d'obtention d'une solution d'anticorps exempte d'excipient
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
WO2012059598A2 (fr) 2010-11-05 2012-05-10 Novartis Ag Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
EP3681483B1 (fr) 2017-09-15 2022-05-18 Amgen Inc. Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
IL104470A0 (en) * 1992-01-21 1993-05-13 Cryopharm Corp Process for freezing cells and cell like materials and compositions prepared thereby
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
AP852A (en) * 1995-06-07 2000-06-16 Quadrant Holdings Cambridge Ltd Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby.
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
KR20100031769A (ko) * 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US7449444B2 (en) 2002-03-15 2008-11-11 Wyeth Hydroxyethyl starch-containing polypeptide compositions
WO2010066634A1 (fr) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Procédé d'obtention d'une solution d'anticorps exempte d'excipient
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
WO2012059598A2 (fr) 2010-11-05 2012-05-10 Novartis Ag Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
EP3542820A1 (fr) 2010-11-05 2019-09-25 Novartis AG Méthodes de traitement de la polyarthrite psoriasique au moyen d'antagonistes d'il-17
EP3912640A1 (fr) 2010-11-05 2021-11-24 Novartis AG Compositions pharmaceutiques contenant secukinumab
EP4116325A1 (fr) 2010-11-05 2023-01-11 Novartis AG Procédés de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
EP3681483B1 (fr) 2017-09-15 2022-05-18 Amgen Inc. Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique
US12251474B2 (en) 2017-09-15 2025-03-18 Amgen Inc. Process for lyophilized pharmaceutical formulations of a therapeutic protein

Also Published As

Publication number Publication date
TW200303213A (en) 2003-09-01
JP2005508992A (ja) 2005-04-07
MXPA04004459A (es) 2005-05-16
WO2003041637A3 (fr) 2004-01-22
AR037304A1 (es) 2004-11-03
CA2466641A1 (fr) 2003-05-22
EP1455822A4 (fr) 2004-12-29
EP1455822A2 (fr) 2004-09-15

Similar Documents

Publication Publication Date Title
US20240058263A1 (en) Formulations of antibody
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
AU772940B2 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
US10786567B2 (en) Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
KR101273568B1 (ko) 약제학적 항-종양 괴사 인자-α 항체 제제
KR102605317B1 (ko) 실온 안정성 동결건조된 단백질
CA2693611A1 (fr) Nouvelle formulation
WO2018124948A1 (fr) Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α
WO2003041637A2 (fr) Compositions lyophilisees d'anticorps monoclonaux
AU2002337895A1 (en) Lyophilized monoclonal antibody compositions
RU2665966C2 (ru) Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
CN115998690B (zh) 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
WO2016059593A1 (fr) Composition injectable stable de médicaments protéiques et procédé de préparation associé
BRPI9715268B1 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002337895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004459

Country of ref document: MX

Ref document number: 2003543524

Country of ref document: JP

Ref document number: 2466641

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002773798

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002773798

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002773798

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载